trial · primary record
Trastuzumab Deruxtecan
Endometrial Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 710 |
| Primary completion | 2032-03-23 |
| Primary endpoint | Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review or by Histopathologic Confirmation of Disease Recurrence per Local Assessment |
| Registry ID | NCT07022483 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:10.726Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07022483
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.